NCT05272384

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2022-11-03Est. Completion: 2027-06-28

Enrollment target: 32 participants

Locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Yale University, New Haven, Connecticut, United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
NYU Langone Hospital - Long Island, Mineola, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

Other microbiome trials you might be interested in

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignanciesPhase 1Recruiting

Acute LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Biphenotypic LeukemiaAcute Undifferentiated LeukemiaCLL (Chronic Lymphocytic Leukemia)Chronic Myeloid Leukemia (CML)MDS (Myelodysplastic Syndrome)Non-Hodgkin LymphomasHodgkins LymphomaCutaneous T Cell Lymphomas (CTCL)

The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marro…

Duarte, United StatesEst. completion Jul 14, 2026

View Trial →

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.